Journal of Drugs in Dermatology最新文献

{"title":"Histological Analysis Shows That a Moisturizer Formulated for Dermatoporosis Increases Elastin Content and Improves Skin Elasticity.","authors":"Glynis Ablon, Todd Schlesinger, Christine Emesiani, Sindhu Garimella, Thu Q Nguyen, Alan Widgerow, Jean Philippe York, Matthew Meckfessel","doi":"10.36849/JDD.10248","DOIUrl":"https://doi.org/10.36849/JDD.10248","url":null,"abstract":"<p><strong>Background: </strong>Dermatoporosis involves age-related alterations in dermal structure and cellular function, including changes in collagen, elastin, and markers of skin senescence. Changes in skin biomarkers (collagen I, elastin, senescence-associated beta-galactosidase, CD44, and CD47) were assessed following the use of a novel moisturizer, GC (Galderma Laboratories, L.P., Fort Worth, TX), by subjects with mature, aging skin.</p><p><strong>Methods: </strong>This 12-week multisite study recruited female and male subjects aged 40 to 60 years of all races, ethnicities, and Fitzpatrick skin types. Subjects were required to have a history of fragile skin and dry, crepey skin on the knees. The GC cream was applied to the knee and thigh skin twice daily. A subset of 5 patients underwent 3-mm punch biopsies on the upper knee at baseline and week 12 for immunohistochemistry. Standardized photography of skin appearance and pinch-release tests were conducted at baseline and weeks 4, 8, and 12.</p><p><strong>Results: </strong>With GC cream use, elastin expression increased from baseline to week 12 (18% to 36%; P&lt;.05) and beta-galactosidase expression trended higher (18% to 24%). Expression of CD44 (91% to 92%), CD47 (81% to 82%), and collagen type I alpha 1 (94% at both timepoints) was stable. Subjects' skin firmness and appearance were visibly improved.</p><p><strong>Conclusion: </strong>After 12 weeks of twice-daily use of the GC cream, there was a significant increase in elastin expression, which was accompanied by visual improvement in skin elasticity and texture. These data validate clinical histological findings and show how topical intervention can improve overall skin health. &nbsp.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 10","pages":"962-966"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":": Real-World Cases Using Phyto Polydeoxyribonucleotide (PDRN) Serum.","authors":"Yan Wu, Sophie Guénin, Elaine Fung, Patricia Brieva, Xiaoning Li, Liang-Chen Lin, Carlos Morales Raya, Marco Rocha, Karim Sayed, Todd Schlesinger, John Sullivan, Jill Waibel","doi":"10.36849/JDD.15491","DOIUrl":"https://doi.org/10.36849/JDD.15491","url":null,"abstract":"<p><strong>Background: </strong>Integrative skincare refers to a clinician-directed regimen that combines aesthetic procedures with appropriate post-procedure skincare. The novel phyto polydeoxyribonucleotides (PDRN) formulation combines the benefits associated with the antioxidant, soothing phyto botanical blend with the effects of PDRN, a regenerative ingredient for wound-healing with collagen-stimulating properties. The serum contains an 8% phyto botanical complex, ectoin, tripeptide-8, and a 9.7% hydrating complex (glycerin and hyaluronic acid), along with PDRN derived from Lactobacillus sakei, a bacterium isolated from the soil of fallen magnolia flowers. Together, these components are designed to reduce immediate post-procedure redness and erythema while providing skin-rejuvenating benefits with continued use.</p><p><strong>Methods: </strong>Nine global expert medical doctors share their experience incorporating the serum into post-procedure care with the goal of optimizing patient outcomes and minimizing downtime. The phyto PDRN serum was evaluated in a split-face real-world protocol for post-procedure care.</p><p><strong>Results: </strong>Eight cases were selected by the expert panel to demonstrate the use of the phyto PDRN serum in an integrative skincare treatment plan under real-world conditions. All cases demonstrated successful integration of the phyto PDRN serum into the post-procedure care of eight women with Fitzpatrick skin types II&ndash;IV and aged from 28 to 68. Patients underwent non-ablative fractional laser, Nd:YAG, microneedling, microneedling radiofrequency, and chemical peels to address their various skin concerns.</p><p><strong>Conclusion: </strong>The phyto PDRN serum was safe, well-tolerated, and a clinically useful adjunct to integrative skin care regimens following cosmetic procedures. The antioxidant and anti-inflammatory ingredients, combined with PDRN polymers, uniquely support post-procedure recovery and skin repair.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 9","pages":"15491s2-15491s14"},"PeriodicalIF":2.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardized Suture Tail Cutting Technique for Enhanced Cosmesis in Epidermal Closure.","authors":"Milan V Carter, Amanda Rosenthal, Justin Marson, Nima Gharavi","doi":"10.36849/JDD.10116","DOIUrl":"https://doi.org/10.36849/JDD.10116","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 9","pages":"e83-e84"},"PeriodicalIF":2.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Moisturizer Formulated With Micronized Centella asiatica and Mandelic Acid Improves Mature, Crepey Skin.","authors":"Glynis Ablon, Christine Emesiani, Sindhu Garimella, Matthew Meckfessel, Thu Q Nguyen, Alan Widgerow, Todd Schlesinger","doi":"10.36849/JDD.10191","DOIUrl":"10.36849/JDD.10191","url":null,"abstract":"<p><strong>Background: </strong>Dermatoporosis is a condition of fragile, aging skin that manifests as altered pH, wrinkles, laxity, easy bruising, and hyperpigmentation. This study evaluated efficacy, safety, and subject perception after the use of a novel cream, GC (Galderma Laboratories, LP, Fort Worth, TX), on subjects with mature, aging skin.</p><p><strong>Methods: </strong>A 12-week multicenter, randomized, blinded, in-use study enrolled female and male subjects aged 40 to 60 years of all races, ethnicities, and Fitzpatrick skin types. Subjects were required to have a history of fragile skin and dry, crepey skin on the knees and thighs. GC cream was applied to knee and upper thigh skin twice daily. Assessments included clinical grading, digital photography, bioinstrumentation (skin texture, pH, and heatmap hydration), standard safety assessments, and satisfaction.</p><p><strong>Results: </strong>Use of GC cream for 12 weeks resulted in significant improvements in skin crepiness, photodamage, and firmness, as well as decreased skin pH and early improvements in skin roughness and smoothness from baseline. Corneometer heatmapping documented improved skin hydration over baseline. No adverse events were reported; the GC cream was well tolerated, and subjects reported high satisfaction.</p><p><strong>Conclusion: </strong>Twice-daily application of the novel GC skin cream significantly improved the overall skin quality of mature, aging skin, including crepiness, photodamage, firmness, texture, pH, and hydration. GC cream was well tolerated with high subject satisfaction. These data are intended to help guide healthcare providers and patients in choosing an effective moisturizer that was specifically designed for patients with fragile, mature skin.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 9","pages":"833-838"},"PeriodicalIF":2.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Corticosteroids in the Perioperative Setting for Prevention of Pyoderma Gangrenosum During Reconstructive Surgery.","authors":"Lindsay Skylar Li, William C Lau, Mark Lebwohl","doi":"10.36849/JDD.9605","DOIUrl":"https://doi.org/10.36849/JDD.9605","url":null,"abstract":"<p><p>Pyoderma gangrenosum (PG) is classified as a neutrophilic dermatosis, often presenting as a rapidly enlarging ulcer and associated with inflammatory bowel disease, specifically ulcerative colitis and Crohn's disease. PG has been typically reported to occur after trauma and surgical procedures. We present a unique case of PG following multiple breast augmentation procedures and illustrate various therapeutic strategies to prevent recurrence during subsequent breast reconstruction. The combination of cyclosporine and prednisone was successfully used to prevent PG in this patient when given before and after her third breast surgery. &nbsp; &nbsp.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 9","pages":"865-867"},"PeriodicalIF":2.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Keloid and Hypertrophic Scar Treatment Patterns by Race.","authors":"Robert Adler, Michael Kozlov, Shrividhya Babu, Isha Gandhi, Manan D Mehta, Emily Cowen, Katerina Svigos, Justin Wu Marson, Jessica Lori Feig","doi":"10.36849/JDD.9651","DOIUrl":"https://doi.org/10.36849/JDD.9651","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 9","pages":"e81-e82"},"PeriodicalIF":2.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of Primary Closure in Nasal Reconstruction: A Case Series Research Letter.","authors":"Connor K Sisk, Scott C Jaros, Hamza Malick, Umer Nadir, Stanislav N Tolkachjov","doi":"10.36849/JDD.10150","DOIUrl":"https://doi.org/10.36849/JDD.10150","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 9","pages":"e85-e86"},"PeriodicalIF":2.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Sirolimus for Refractory Cutis Marmorata Telangiectatica Congenita in Adulthood: A Case Report.","authors":"Ram D Bhatt, Kateryna Karpoff, Nicholas Heitman, Rabail Aslam, Mark Lebwohl","doi":"10.36849/JDD.9757","DOIUrl":"https://doi.org/10.36849/JDD.9757","url":null,"abstract":"<p><p>Cutis marmorata telangiectatica congenita (CMTC) is a rare congenital vascular disorder characterized by persistent, violaceous, reticulated skin changes that may be complicated by painful ulcerations. Although localized disease often improves with age, generalized CMTC can persist into adulthood and may be associated with limb asymmetry, ocular abnormalities, and neurologic sequelae. Diagnosis can be challenging in atypical adult presentations despite established major and minor criteria. We report a case of a 50-year-old woman with congenital livedo reticularis and Raynaud syndrome who presented with lifelong unilateral left lower-extremity hypoplasia and fixed lacy violaceous patches. Over the preceding decade, she developed recurrent, spontaneous, painful ulcerations exacerbated by cold exposure. Examination revealed a hypoplastic left leg with reticulated violaceous patches and tender, crusted erosions without venectasia; biopsy findings ruled out vasculitis, and the overall clinicopathologic picture met all three major and multiple minor Kienast-Hoeger criteria for CMTC. Multiple therapies targeting vasospasm and microvascular flow (including sildenafil, pentoxifylline, diosmiplex, nifedipine, and aspirin) failed to improve symptoms. Initiation of once-daily topical sirolimus (1 mg/mL) resulted in marked pain reduction within four weeks and cessation of new ulcerations, with visible improvement and healed erosions by two months. This case supports topical sirolimus as a promising off-label option for adult CMTC with chronic ulcerative disease.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 9","pages":"868-869"},"PeriodicalIF":2.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK/STAT Inhibitors Reduce Risk of New-Onset Keloids and Hypertrophic Scars: A Multi-Center Retrospective Cohort Study.","authors":"Robert Adler, Fariha Ahmed, Michael Kozlov, Navid Ashrafi, Neal Gupta, Manan D Mehta, Katerina Svigos, Jessica L Feig, Jared R Jagdeo","doi":"10.36849/JDD.9800","DOIUrl":"10.36849/JDD.9800","url":null,"abstract":"<p><strong>Background: </strong>Keloids and hypertrophic scars are fibroproliferative skin disorders characterized by excessive collagen deposition and high recurrence rates despite existing therapies. Emerging evidence implicates immune-mediated pathways, including Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling, in their pathogenesis. However, population-level data evaluating the association between JAK inhibitor exposure and keloid/hypertrophic scar risk are lacking.</p><p><strong>Objective: </strong>To evaluate whether initiation of JAK inhibitors is associated with a reduced risk of incident hypertrophic scar or keloid formation.</p><p><strong>Methods: </strong>Using a target trial emulation framework, we conducted a retrospective cohort study within the TriNetX US Collaborative Network. Adults without prior hypertrophic scar or keloid formation were classified as initiators of a JAK inhibitor or psoriasis comparators without JAK inhibitor exposure. Propensity score matching (1:1) balanced demographic characteristics, comorbidities, healthcare utilization, trauma history, and surgical exposure. The primary outcome was incident hypertrophic scar or keloid formation (ICD-10-CM L91.0) within 730 days. Risk ratios (RRs) and Cox proportional hazards models were used to estimate cumulative and time-to-event associations.</p><p><strong>Results: </strong>After matching, 122,341 individuals were included in each group. Within two years, hypertrophic scar or keloid formation occurred in 0.14% of JAK inhibitor initiators versus 0.22% of comparators (RR 0.65, 95% CI 0.54-0.79; absolute risk difference -0.08%; P&lt;0.001). JAK inhibitor initiation was also associated with a lower hazard of scar formation (HR 0.77, 95% CI 0.64-0.93).</p><p><strong>Conclusion: </strong>Initiation of JAK inhibitors was associated with a significantly reduced risk of incident hypertrophic scar or keloid formation. These findings support a potential role for JAK/STAT pathway modulation in keloid prevention and warrant prospective investigation. &nbsp.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 9","pages":"779-784"},"PeriodicalIF":2.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardamonin Inhibits Keloid Fibroblast Activation and Extracellular Matrix Production Through Suppression of TGF-β1/Smad Signaling.","authors":"Meijing Jin, Changzhe Jing, Hongmei Liu, Bo Lu, Zhezhu Jin, Minhao Piao, Zhehu Jin, Xinghua Yuan","doi":"10.36849/JDD.9945","DOIUrl":"https://doi.org/10.36849/JDD.9945","url":null,"abstract":"<p><strong>Background: </strong>Keloids are pathological scars characterized by persistent fibroblast activation and excessive extracellular matrix (ECM) deposition. Cardamonin (CARD), a natural chalcone compound, has demonstrated anti-fibrotic effects; however, its role in keloid-associated fibrosis remains unclear. This study aimed to investigate the effects of CARD on human keloid fibroblasts (KFs) and the underlying molecular mechanisms.</p><p><strong>Methods: </strong>A human keloid fibroblast cell line (KEL FIB) was treated with increasing concentrations of CARD. Cell proliferation, clonogenic growth, apoptosis, migration, and invasion were assessed using CCK-8, colony formation, flow cytometry, wound healing, and Transwell assays. Myofibroblast markers and ECM-related proteins were analyzed by immunofluorescence, RT-qPCR, and western blotting. TGF-&beta;1/Smad signaling was evaluated by assessing Smad2/3 phosphorylation.</p><p><strong>Results: </strong>CARD inhibited KF proliferation, migration, and invasion in a dose-dependent manner and promoted apoptosis through modulation of the BAX/BCL2 ratio and activation of Caspase-3. CARD reduced &alpha;-SMA and vimentin expression and decreased collagen I, collagen III, and fibronectin expression. CARD also attenuated TGF-&beta;1-induced Smad2/3 phosphorylation.</p><p><strong>Conclusion: </strong>Cardamonin exerts anti-fibrotic effects in human keloid fibroblasts by suppressing the TGF-&beta;1/Smad signaling pathway, suggesting its potential as a pharmacological candidate for the treatment of keloids.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 9","pages":"857-864"},"PeriodicalIF":2.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}